The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC).
Toshio Otsuji
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Kentaro Yamazaki
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Hitoshi Ojima
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Hiroyuki Kuwano
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Takeshi Kato
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical
Ken Shimada
Honoraria - Taiho Pharmaceutical
Tadamichi Denda
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Taito Esaki
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Ichinosuke Hyodo
Consultant or Advisory Role - Taiho Pharmaceutical; Yakult Honsha
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
Narikazu Boku
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha